[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615677":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ALN-4285","EXPERIMENTAL","Participants will be administered ALN-4285 subcutaneously (SC)",[13],"Drug: ALN-4285",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will be administered placebo SC",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ALN-4285 will be administered SC",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo will be administered SC",[15],[30],{"name":31,"affiliation":5,"role":32},"Medical Director","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":35,"role":36,"phone":40,"phoneExt":25,"email":38},"1-877-256-9526",[42],{"facility":43,"status":44,"city":45,"state":25,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":25},"Clinical Trial Site","RECRUITING","London","NW10 7EW","United Kingdom","UK",{"type":50,"coordinates":51},"Point",[52,53],-0.12574,51.50853,{"lat":53,"lon":52},{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100615677","phase-1-a-study-to-evaluate-aln-4285-in-adult-healthy-volunteers-100615677",false,"NCT07295717","A Study to Evaluate ALN-4285 in Adult Healthy Volunteers","A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers","Inclusion Criteria:\n\n* Has a body mass index (BMI) of ≥18.0 kg\u002Fm\\^2 and ≤30 kg\u002Fm\\^2\n* Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator\n\nExclusion Criteria:\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>upper limit of normal (ULN)\n* Has total bilirubin \\>ULN\n* Has systolic blood pressure \\>140 mmHg and\u002For a diastolic blood pressure \\>90 mmHg\n* Has an estimated glomerular filtration (eGFR) of \\\u003C90 mL\u002Fmin\u002F1.73m\\^2 at screening\n* Has received an investigational agent within the last 30 days or 5 half-lives",true,"ALL","18 Years","65 Years",{"count":69,"type":70},76,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","The purpose of this study is to:\n\n* evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers\n* characterize the single-dose pharmacokinetics (PK) of ALN-4285",[76],"Healthy Volunteers",[78,79],"siRNA","RNAi therapeutics","2026-06-10",{"date":82,"type":83},"2026-06-12","ACTUAL",{"date":85,"type":83},"2025-12-12",{"date":87,"type":70},"2027-03-23",{"name":5,"class":6},1]